9 METERS BIOPHARMA, INC.

$ Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000155198619000046 Filed on May 10, 2019

Income Statement

Concept	2019 Q2	2019 Q1	2018 Q1

Balance Sheet

Concept	2019 Q2	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$13.34M	$11.49M	$12.98M
YoY Change	25.14%	-11.48%	8553.33%
Cash & Equivalents	$13.34M	$11.49M	$12.98M
Short-Term Investments
Other Short-Term Assets	$1.200M	$980.0K	$250.0K
YoY Change	400.0%	292.0%	-40.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$14.53M	$12.47M	$13.23M
YoY Change	33.21%	-5.7%	551.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$34.16K	$29.96K	$51.96K
YoY Change	-24.72%	-42.35%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.580K	$5.580K	$5.580K
YoY Change	0.0%	0.0%	-44.2%
Total Long-Term Assets	$109.1K	$117.5K	$57.54K
YoY Change	114.05%	104.25%	-97.59%
TOTAL ASSETS
Total Short-Term Assets	$14.53M	$12.47M	$13.23M
Total Long-Term Assets	$109.1K	$117.5K	$57.54K
Total Assets	$14.64M	$12.59M	$13.29M
YoY Change	33.59%	-5.23%	200.57%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.712M	$3.929M	$2.025M
YoY Change	-18.98%	94.01%	202.23%
Accrued Expenses	$974.1K	$897.3K	$5.928K
YoY Change		15035.88%	-99.6%
Deferred Revenue
YoY Change
Short-Term Debt	$4.040M	$3.740M	$3.410M
YoY Change	-2.65%	9.68%	8425.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.619M	$10.94M	$5.439M
YoY Change	28.25%	101.22%	58.1%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$10.00K	$30.00K
YoY Change
Total Long-Term Liabilities	$10.00K	$30.00K	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.619M	$10.94M	$5.439M
Total Long-Term Liabilities	$10.00K	$30.00K	$0.00
Total Liabilities	$9.633M	$10.97M	$5.440M
YoY Change	28.44%	101.71%	58.14%
SHAREHOLDERS EQUITY
Retained Earnings	-$52.44M	-$47.95M	-$34.31M
YoY Change	36.1%	39.74%
Common Stock	$3.589K	$3.107K	$2.569K
YoY Change	39.65%	20.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.006M	$1.618M	$7.846M
YoY Change
Total Liabilities & Shareholders Equity	$14.64M	$12.59M	$13.29M
YoY Change	33.59%	-5.23%	200.57%

Cashflow Statement

Concept	2019 Q2	2019 Q1	2018 Q1

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	innt	Adjustments To Additional Paid In Capital Allocation Of Warrants To Liabilities AdjustmentsToAdditionalPaidInCapitalAllocationOfWarrantsToLiabilities	-1970000	USD
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001551986
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35383874	shares
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	INNOVATE BIOPHARMACEUTICALS, INC.
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q1	dei	Trading Symbol TradingSymbol	INNT
CY2019Q1	innt	Adjustments To Additional Paid In Capital Warrant Issued To Placement Agents AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToPlacementAgents	913000	USD
CY2018Q1	innt	Adjustments To Additional Paid In Capital Warrant Issued To Placement Agents AdjustmentsToAdditionalPaidInCapitalWarrantIssuedToPlacementAgents	913000	USD
CY2019Q1	innt	Capital Stock Authorized CapitalStockAuthorized	360000000	shares
CY2018Q1	innt	Convertible Promissory Notesbeneficial Conversion Feature ConvertiblePromissoryNotesbeneficialConversionFeature	3077887	USD
CY2019Q1	innt	Convertible Promissory Notesbeneficial Conversion Feature ConvertiblePromissoryNotesbeneficialConversionFeature	0	USD
CY2018Q3	innt	Estimated Clinical Trial Data Management Fee EstimatedClinicalTrialDataManagementFee	1100000	USD
CY2018Q1	innt	Exchange Ratio In Connection With Merger ExchangeRatioInConnectionWithMerger	0.37686604
CY2018Q1	innt	Gain Losson Extinguishmentof Derivative Liability GainLossonExtinguishmentofDerivativeLiability	0	USD
CY2019Q1	innt	Gain Losson Extinguishmentof Derivative Liability GainLossonExtinguishmentofDerivativeLiability	370000	USD
CY2016	innt	Milestone Fee Free Sales Target Value MilestoneFeeFreeSalesTargetValue	1500000000	USD
CY2019Q1	innt	Net Proceeds From Issuance Of Common Stock After Deducting Stock Issuance Costs NetProceedsFromIssuanceOfCommonStockAfterDeductingStockIssuanceCosts	16500000	USD
CY2018Q1	innt	Noncash Addition Of Deferred Offering Costs NoncashAdditionOfDeferredOfferingCosts	0	USD
CY2019Q1	innt	Noncash Addition Of Deferred Offering Costs NoncashAdditionOfDeferredOfferingCosts	151137	USD
CY2018Q1	innt	Noncash Addition Of Derivative Liability NoncashAdditionOfDerivativeLiability	0	USD
CY2019Q1	innt	Noncash Addition Of Derivative Liability NoncashAdditionOfDerivativeLiability	1281000	USD
CY2019Q1	innt	Number Of Former Executives NumberOfFormerExecutives	2	executive
CY2019Q1	innt	Number Of Stock Option Plans NumberOfStockOptionPlans	2	plan
CY2019Q1	innt	Number Of Warrants Issued NumberOfWarrantsIssued	1400000	shares
CY2017Q4	innt	Operating Lease Annual Rental Payments OperatingLeaseAnnualRentalPayments	60000	USD
CY2018Q4	innt	Operating Lease Monthly Rental Payments OperatingLeaseMonthlyRentalPayments	5000	USD
CY2018	innt	Payments To Executives PaymentsToExecutives	1100000	USD
CY2019Q1	innt	Placement Agent Fees PlacementAgentFees	1600000	USD
CY2014	innt	Royalties Payment Expiration Requirement RoyaltiesPaymentExpirationRequirement	P10Y
CY2018Q1	innt	Saleof Stock Shares Issuable Upon Exerciseof Warrant SaleofStockSharesIssuableUponExerciseofWarrant	2051771	shares
CY2018Q1	innt	Saleof Stock Shelf Registration Maximum Equity Offering Price SaleofStockShelfRegistrationMaximumEquityOfferingPrice	175000000	USD
CY2018Q1	innt	Saleof Stock Stockholders Aggregate Shares Availableforsale SaleofStockStockholdersAggregateSharesAvailableforsale	13990403	shares
CY2019Q1	innt	Severance Costs Equal Installment Period SeveranceCostsEqualInstallmentPeriod	P12M
CY2018Q1	innt	Severance Provisions Annual Base Salary Period SeveranceProvisionsAnnualBaseSalaryPeriod	P12M
CY2018Q1	innt	Severance Provisions Continuation Of Health Insurance Benefits Period SeveranceProvisionsContinuationOfHealthInsuranceBenefitsPeriod	P12M
CY2018Q1	innt	Stock Issued During Period Value Stock Splits StockIssuedDuringPeriodValueStockSplits	-978674	USD
CY2018Q4	innt	Warrant Liability Current WarrantLiabilityCurrent	0	USD
CY2019Q1	innt	Warrant Liability Current WarrantLiabilityCurrent	1113000	USD
CY2018Q1	innt	Warrants Issued To Placement Agents WarrantsIssuedToPlacementAgents	913000	USD
CY2019Q1	innt	Warrants Issued To Placement Agents WarrantsIssuedToPlacementAgents	0	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3618634	USD
CY2019Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	3928685	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	826327	USD
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	897255	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	39854297	USD
CY2019Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49565235	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	3077887	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7174000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	526000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2568079	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	319819	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Split AdjustmentsToAdditionalPaidInCapitalStockSplit	0	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	2000000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1995000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7174000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	526000	USD
CY2018Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	427866	USD
CY2019Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	74803	USD
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8755145	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15786020	shares
CY2018Q4	us-gaap	Assets Assets	6454188	USD
CY2019Q1	us-gaap	Assets Assets	12590481	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	6413513	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	12472953	USD
CY2018Q4	us-gaap	Cash Cash	5728900	USD
CY2019Q1	us-gaap	Cash Cash	11494894	USD
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	697334	USD
CY2019Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	659352	USD
CY2018Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	154403	shares
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2293000	USD
CY2018Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	12981599	shares
CY2019Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	20868638	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2019Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-857000	USD
CY2019Q1	us-gaap	Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	958000	USD
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	370000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	355563	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12976711	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5728900	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11494894	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	12621148	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5765994	USD
CY2018Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	75000	USD
CY2019Q1	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	75000	USD
CY2019Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	6689702	shares
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	26088820	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31065602	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	26088820	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	31065602	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	2609	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	3107	USD
CY2018Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	5196667	USD
CY2019Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	3736803	USD
CY2019Q1	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	500000	USD
CY2018Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	104706	USD
CY2019Q1	us-gaap	Deferred Offering Costs DeferredOfferingCosts	100056	USD
CY2018Q1	us-gaap	Depreciation Depreciation	2688	USD
CY2019Q1	us-gaap	Depreciation Depreciation	5139	USD
CY2018Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2019Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	471000	USD
CY2018Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	370000	USD
CY2019Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1180000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.70
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4434765	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	427245	USD
CY2019Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1049166	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4970613	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3114495	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14959744	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1612347	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	163564	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1014502	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	70928	USD
CY2018Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	USD
CY2019Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-101000	USD
CY2018Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	0	USD
CY2019Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-101624	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	88917	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	298096	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	3661619	USD
CY2018Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	25578	USD
CY2019Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	35139	USD
CY2018Q1	us-gaap	Interest Income Other InterestIncomeOther	30492	USD
CY2019Q1	us-gaap	Interest Income Other InterestIncomeOther	26456	USD
CY2018Q1	us-gaap	Interest Paid Net InterestPaidNet	130288	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	418927	USD
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	101624	USD
CY2019Q1	us-gaap	Interest Payable Current InterestPayableCurrent	35139	USD
CY2018Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	15000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	90000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	45000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	45000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8008	USD
CY2019Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P2Y
CY2017Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P2Y
CY2017Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2018Q4	us-gaap	Liabilities Liabilities	10113252	USD
CY2019Q1	us-gaap	Liabilities Liabilities	10972874	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6454188	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12590481	USD
CY2018Q1	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	978674	USD
CY2019Q1	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	0	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10113252	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	10943896	USD
CY2018Q4	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	3600000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19527582	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10003740	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	61057	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6967491	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4237746	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-14959744	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-4434765	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3631127	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-121955	USD
CY2019Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	11328617	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	4312810	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	11328617	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	4312810	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	15000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	81992	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	53014	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	28978	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	100000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	81992	USD
CY2018Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P24M
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	128993	USD
CY2019Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	237903	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5580	USD
CY2019Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5580	USD
CY2018Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	20000	USD
CY2019Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	57000	USD
CY2018Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1655079	USD
CY2019Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	168682	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13943	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2019Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	504907	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	803003	USD
CY2018Q1	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	75000	USD
CY2019Q1	us-gaap	Proceeds From Collection Of Longterm Loans To Related Parties ProceedsFromCollectionOfLongtermLoansToRelatedParties	0	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18100000	USD
CY2019Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	5000000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	18132661	USD
CY2018Q1	us-gaap	Stock Issued1 StockIssued1	9229336	USD
CY2019Q1	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11475255	USD
CY2019Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	9700000	USD
CY2018Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	3345000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35095	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	29956	USD
CY2018Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	275000	USD
CY2019Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	6245833	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6358004	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1198315	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43515970	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-47950735	USD
CY2019Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	4181068	shares
CY2017Q4	us-gaap	Security Deposit SecurityDeposit	5000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7174000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	526000	USD
CY2019Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.33
CY2018Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	9229819	USD
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16137661	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11475255	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-12174614	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	7846256	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-3659064	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	1617607	USD
CY2018Q1	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.10
CY2019Q1	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21243905	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27252278	shares
CY2019Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Areas of the financial statements where estimates may have the most significant effect include accrued expenses, share-based compensation, valuation of the derivative liability and warrant liability, valuation allowance for income tax assets and management’s assessment of the Company’s ability to continue as a going concern. Changes in the facts or circumstances underlying these estimates could result in material changes and actual results could differ from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001551986-19-000046-index-headers.html	Edgar Link	pending
0001551986-19-000046-index.html	Edgar Link	pending
0001551986-19-000046.txt	Edgar Link	pending
0001551986-19-000046-xbrl.zip	Edgar Link	pending
ex311q12019.htm	Edgar Link	pending
ex312q12019.htm	Edgar Link	pending
ex321q12019.htm	Edgar Link	pending
ex322q12019.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
innt-20190331.xml	Edgar Link	completed
innt-20190331.xsd	Edgar Link	pending
innt-20190331_cal.xml	Edgar Link	unprocessable
innt-20190331_def.xml	Edgar Link	unprocessable
innt-20190331_lab.xml	Edgar Link	unprocessable
innt-20190331_pre.xml	Edgar Link	unprocessable
innt331201910-q.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

9 METERS BIOPHARMA, INC.

2019 Q2 Form 10-Q Financial Statement

#000155198619000046 Filed on May 10, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission